A LinkedIn post from Pulnovo Medical indicates that the company plans to present landmark data from its PADN-Columbus Trial at EuroPCR 2026 in Paris. The post describes the study as the first European clinical evidence for pulmonary artery denervation (PADN) in Group 2 pulmonary hypertension due to left heart disease, an area the company suggests currently lacks approved therapies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post outlines multiple scientific sessions featuring PADN technology, including a talk on radio-frequency PADN for pulmonary hypertension and a dedicated unveiling of the PADN-Columbus results. The company also highlights a strong presence on the exhibition floor with interactive booth sessions and networking events, positioning itself as an active participant in the evolving pulmonary vascular intervention space.
For investors, the emphasis on first-in-Europe evidence may signal a critical validation step for Pulnovo Medical’s PADN platform in a large, underserved patient population. If subsequent peer-reviewed data and regulatory pathways align, the trial could potentially enhance the company’s clinical credibility, support future commercialization efforts in cardiovascular interventions, and improve its competitive positioning within the medtech sector.